ES2099362T3 - Derivados de octahidrofenantreno. - Google Patents

Derivados de octahidrofenantreno.

Info

Publication number
ES2099362T3
ES2099362T3 ES93121161T ES93121161T ES2099362T3 ES 2099362 T3 ES2099362 T3 ES 2099362T3 ES 93121161 T ES93121161 T ES 93121161T ES 93121161 T ES93121161 T ES 93121161T ES 2099362 T3 ES2099362 T3 ES 2099362T3
Authority
ES
Spain
Prior art keywords
hydrogen
combinations
halogen
amino
mean
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93121161T
Other languages
English (en)
Inventor
Thierry Godel
Eva-Maria Gutknecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2099362T3 publication Critical patent/ES2099362T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/52—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/70—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

COMBINACIONES DE LA FORMULA GENERAL I, EN LA QUE R1 Y R2 SIGNIFICAN CADA UNO HIDROGENO O EN CASO DADO ALQUILO BAJO SUSTITUIDO POR ARILO O CICLOALQUILO-C3-6; R4 Y R5 SIGNIFICAN O BIEN LOS DOS HIDROGENO O LOS DOS HALOGENO, O UNO HIDROGENO Y EL OTRO HALOGENO, HIDROXI, ALCOXI BAJO, ARILOXI O AMINO Y R3 SIGNIFICA HIDROGENO O EN CASO DE QUE NO EXISTA NINGUN GRUPO O GRUPOS PRIMARIO O SECUNDARIO, ALCANOILO, ASI COMO SALES DE EMPLEO FARMACEUTICO DE COMBINACIONES DE LA FORMULA I CON ACIDOS QUE POSEEN VALIOSAS PROPIEDADES FARMACODINAMICAS COMO ANTAGONISTAS NMDA NO COMPETITIVOS, DE FORMA QUE SE PUEDEN EMPLEAR COMO NEUROPROTECTORES. ESTAS COMBINACIONES SON NUEVAS, CON EXCEPCION DE RAC-CIS-4B(2-AMINO-ETILO)4B,5,6,7,8,8A,9.10-OCTAHIDROFENANTRENO8A-OL.
ES93121161T 1993-01-15 1993-12-31 Derivados de octahidrofenantreno. Expired - Lifetime ES2099362T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH12393 1993-01-15

Publications (1)

Publication Number Publication Date
ES2099362T3 true ES2099362T3 (es) 1997-05-16

Family

ID=4179785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93121161T Expired - Lifetime ES2099362T3 (es) 1993-01-15 1993-12-31 Derivados de octahidrofenantreno.

Country Status (22)

Country Link
US (1) US5385947A (es)
EP (1) EP0606661B1 (es)
JP (1) JP2505978B2 (es)
KR (1) KR940018355A (es)
CN (1) CN1097727A (es)
AT (1) ATE150001T1 (es)
AU (1) AU668442B2 (es)
BR (1) BR9400082A (es)
CA (1) CA2111138A1 (es)
CZ (1) CZ8694A3 (es)
DE (1) DE59305763D1 (es)
DK (1) DK0606661T3 (es)
ES (1) ES2099362T3 (es)
FI (1) FI940147A7 (es)
GR (1) GR3023581T3 (es)
HU (1) HUT69688A (es)
IL (1) IL108307A0 (es)
NO (1) NO180630C (es)
NZ (1) NZ250652A (es)
PL (1) PL301905A1 (es)
UY (1) UY23718A1 (es)
ZA (1) ZA94103B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0676196A1 (en) * 1993-10-13 1995-10-11 Otsuka Pharmaceutical Co., Ltd. Nitrogen monoxide synthesis inhibitor
US6197833B1 (en) 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
EP0841906A1 (en) * 1995-07-24 1998-05-20 University Of Florida Research Foundation, Inc. Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells
US6362226B2 (en) 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
DE60112624T2 (de) * 2001-01-04 2006-06-08 Karo Bio Ab Östrogenrezeptor-Liganden und Verfahren
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
DE10140213A1 (de) * 2001-08-16 2003-02-27 Gruenenthal Gmbh Substituierte Octahydrophenanthren-Verbindungen
DE102004015921B4 (de) 2004-03-31 2006-06-14 Infineon Technologies Ag Rückwärts sperrendes Halbleiterbauelement mit Ladungskompensation
SG162724A1 (en) * 2005-05-25 2010-07-29 Janssen Pharmaceutica Nv Process for preparing <alpha s, beta r>-6-bromo-alpha-[2-<dimethylamino>ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
CZ305733B6 (cs) * 2014-08-26 2016-02-24 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Amfifilní sloučeniny s neuroprotektivními účinky

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317910A (en) * 1978-03-20 1982-03-02 E. R. Squibb & Sons, Inc. Benzo-cyclitolamines
US5180736A (en) * 1989-03-23 1993-01-19 Warner-Lambert Company Polycyclic amines useful as cerebrovascular agents
US5071853A (en) * 1989-03-23 1991-12-10 Bigge Christopher F Polycyclic amines useful as cerebrovascular agents

Also Published As

Publication number Publication date
PL301905A1 (en) 1994-07-25
HU9400056D0 (en) 1994-05-30
UY23718A1 (es) 1994-07-06
US5385947A (en) 1995-01-31
NO180630B (no) 1997-02-10
BR9400082A (pt) 1994-08-02
EP0606661B1 (de) 1997-03-12
CZ8694A3 (en) 1994-08-17
NO940143D0 (no) 1994-01-14
HUT69688A (en) 1995-09-28
EP0606661A1 (de) 1994-07-20
ZA94103B (en) 1994-08-19
NZ250652A (en) 1995-10-26
GR3023581T3 (en) 1997-08-29
DE59305763D1 (de) 1997-04-17
FI940147L (fi) 1994-07-16
AU668442B2 (en) 1996-05-02
NO180630C (no) 1997-05-21
NO940143L (no) 1994-07-18
JPH06234711A (ja) 1994-08-23
FI940147A0 (fi) 1994-01-12
CA2111138A1 (en) 1994-07-16
IL108307A0 (en) 1994-04-12
FI940147A7 (fi) 1994-07-16
ATE150001T1 (de) 1997-03-15
AU5311494A (en) 1994-07-21
KR940018355A (ko) 1994-08-16
JP2505978B2 (ja) 1996-06-12
DK0606661T3 (da) 1997-09-01
CN1097727A (zh) 1995-01-25

Similar Documents

Publication Publication Date Title
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
NO902954D0 (no) Fremgangsmaate for fremstilling av substituerte kinazolinoner som angitensin ii-antagonister.
ES2149215T3 (es) Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p.
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
DE69617273D1 (de) Heterocyclisch substituierte cyclopentanderivate.
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
ES2113368T3 (es) Antagonistas de serotonina.
CY1106223T1 (el) Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις
AR248138A1 (es) Un procedimiento de preparacion de acilamino-2-tiazoles.
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
TR200001546T2 (tr) Serin/treonin protein kinaz fonksiyonunu modüle etmek için azabenzimidazol esaslı bileşikler.
DE3855015D1 (de) An Methylamino-Stickstoff substituierte Derivate von Staurosporin
MX9301986A (es) Derivados de perhidroisoindol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE119522T1 (de) Substituierte cyclohexanole mit zentraler nervensystemwirkung.
ES2150039T3 (es) Benzonitrilos como 5-ht agonistas y antagonistas.
TR200101155T2 (tr) 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
ES2172033T3 (es) Inhibidores de farnesil transferasa.
ES2260933T3 (es) Derivados del acido de tiazolina.
ES2059335T3 (es) Derivados de pirido(3,2,1-ij)-1,3,4-benzoxadiazina, procedimiento para su obtencion, preparados farmaceuticos correspondientes y productos intermedios utilizables en el procedimiento.
ES2099755T3 (es) Derivados tripeptidicos de trifluorometilcetona.
ES474592A1 (es) Procedimiento para la preparacion de derivados de imidazoli-nina
UY26513A1 (es) Nuevas piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimiento para su preparación.
ES2088011T3 (es) Antagonistas de aminoacidos excitadores.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 606661

Country of ref document: ES